Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Ho

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Depression and Anxiety|September 14, 2016
Effectiveness of a culturally attuned Internet-based depression prevention program for Chinese adolescents: A randomized controlled trialPatrick Ip, David Chim, Ko Ling Chan, et al.
Kidney International Reports|March 2, 2026
Association of Kidney Volume With Patient-Reported Outcomes in ADPKDJad Fadlallah, Matthew Ho, Muhammad T Hassan, et al.
Blood Cancer Journal|November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myelomaKyle L Yu, Matthew Ho, Luca Paruzzo, et al.
Blood Cancer Journal|September 23, 2021
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Saurabh Zanwar, Prashant Kapoor, et al.
The Journal of Biological Chemistry|December 30, 2018
AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease modelsHuiling Hong, Alex Chun Koon, Zhefan Stephen Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2018
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple MyelomaYan Xu, Shuhui Deng, Xuehan Mao, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
JAMA Network Open|June 10, 2024
Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled TrialVictor Ho-Fun Lee, Varut Vardhanabhuti, Tiffany Cho-Lam Wong, et al.
Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Depression and Anxiety|September 14, 2016
Effectiveness of a culturally attuned Internet-based depression prevention program for Chinese adolescents: A randomized controlled trialPatrick Ip, David Chim, Ko Ling Chan, et al.
Kidney International Reports|March 2, 2026
Association of Kidney Volume With Patient-Reported Outcomes in ADPKDJad Fadlallah, Matthew Ho, Muhammad T Hassan, et al.
Blood Cancer Journal|November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myelomaKyle L Yu, Matthew Ho, Luca Paruzzo, et al.
Blood Cancer Journal|September 23, 2021
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Saurabh Zanwar, Prashant Kapoor, et al.
The Journal of Biological Chemistry|December 30, 2018
AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease modelsHuiling Hong, Alex Chun Koon, Zhefan Stephen Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2018
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple MyelomaYan Xu, Shuhui Deng, Xuehan Mao, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
Leukemia|May 31, 2019
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signalingMatthew Ho, Tianzeng Chen, Jiye Liu, et al.
JAMA Network Open|June 10, 2024
Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled TrialVictor Ho-Fun Lee, Varut Vardhanabhuti, Tiffany Cho-Lam Wong, et al.
Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.
Pageof 8